28 studies found for:    Pharmacyclics | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Conditions: Breast Cancer;   Non-Small Cell Lung Cancer;   Pancreatic Cancer
Interventions: Drug: Ibrutinib;   Drug: MEDI4736
2 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
Condition: Graft Versus Host Disease
Intervention: Drug: Ibrutinib
3 Recruiting Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Conditions: Diffuse Large B Cell Lymphoma Relapsed;   Diffuse Large B Cell Lymphoma Refractory
Interventions: Drug: Ibrutinib, DA-EPOCH-R;   Drug: Ibrutinib, Lenalidomide, DA-EPOCH-R
4 Recruiting A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Conditions: Renal Cell Carcinoma (RCC);   Urothelial Carcinoma;   Gastric Adenocarcinoma;   Colorectal Adenocarcinoma (CRC)
Interventions: Drug: ibrutinib;   Drug: everolimus;   Drug: docetaxel;   Drug: paclitaxel;   Drug: cetuximab
5 Recruiting Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Ibrutinib;   Drug: Gemcitabine;   Drug: Nab-paclitaxel
6 Recruiting Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Rituximab
7 Recruiting informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention:
8 Not yet recruiting Study of Ibrutinib in Combination With Pomalidomide (Pomalyst™) and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Placebo
9 Recruiting A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Conditions: Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Drug: MEDI4736
10 Recruiting A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: Ibrutinib;   Drug: LD-AraC
11 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Drug: Dexamethasone
12 Not yet recruiting First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Ibrutinib;   Drug: Allopurinol;   Drug: Valacyclovir
13 Not yet recruiting Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Drug: obinutuzumab
14 Recruiting Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Ibrutinib
15 Recruiting Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Conditions: Carcinoid Tumors;   Pancreatic NET
Intervention: Drug: Ibrutinib
16 Not yet recruiting Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Secondary Myelodysplastic Syndrome
Interventions: Drug: Azacitidine;   Drug: Ibrutinib
17 Recruiting Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Biological: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Other: Quality-of-Life Assessment;   Biological: Trivalent Influenza Vaccine
18 Recruiting A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
Condition: Lung Cancer
Intervention: Drug: Ibrutinib
19 Recruiting Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: GA101;   Drug: ibrutinib
20 Recruiting Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Conditions: T-cell Lymphoma;   Relapsed and Refractory T-cell Lymphoma
Intervention: Drug: Ibrutinib

   Previous Page Studies Shown (1-20) Next Page (21-28) Show next page of results    Last Page
Indicates status has not been verified in more than two years